LivingGLP1
Study S002095

Cambios en la composición Corporal Tras el Inicio de Agonistas Del Receptor de GLP-1 (GLP-1RA) en Adultos Con Obesidad o Diabetes Tipo 2: Cohorte Prospectiva multicéntrica en Vida Real

ClinicalTrials.gov record

Registration

Registration
NCT07835360
Study type
OBSERVATIONAL
Status
RECRUITING
Enrollment
200
Start
2026-07-10
Primary completion
2029-07
Lead sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Conditions
Obesity (Disorder); Type 2 Diabetes Mellitus
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Change in Appendicular Lean Mass [Baseline, 24 weeks, and 52 weeks]
  • Change in Appendicular Skeletal Muscle Index (ASMI) [Baseline, 24 weeks, and 52 weeks]

Linked records (11)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0002324Fat, muscle, and anti-obesity medications in cardiovascular disease prevention.
Khan MS, European heart journal
2026Other trialPMID 41914150DOIregistry reference BACKGROUND:41914150
R0004650Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Eisa N, Diabetes, obesity & metabolism
2026Systematic reviewPMID 41877354DOIregistry reference BACKGROUND:41877354
R0008599GLP-1 Receptor Agonists.
Rosen CJ, The New England journal of medicine
2026Randomized trialPMID 41931049DOIregistry reference BACKGROUND:41931049
R0012224Genetic predictors of GLP1 receptor agonist weight loss and side effects.
Su QJ, Nature
2026OtherPMID 41951734DOIregistry reference BACKGROUND:41951734
R0001674Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: a 52-week prospective real-life study.
Vozza A, Frontiers in endocrinology
2025Nonrandomized studyPMID 41079186DOIregistry reference BACKGROUND:41079186
R0003168Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.
Thomsen RW, Diabetes, obesity & metabolism
2025Randomized trialPMID 40196933DOIregistry reference BACKGROUND:40196933
R0017139Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Look M, Diabetes, obesity & metabolism
2025Other trialPMID 39996356DOIregistry reference BACKGROUND:39996356
R0005733Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.
Gleason PP, Journal of managed care & specialty pharmacy
2024Nonrandomized studyPMID 38717042DOIregistry reference BACKGROUND:38717042
R0006635Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta-analysis of randomized clinical trials.
Yang W, Obesity reviews : an official journal of the International Association for the Study of Obesity
2024Systematic reviewPMID 38346789DOIregistry reference BACKGROUND:38346789
R0005549Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
He L, JAMA internal medicine
2022Systematic reviewPMID 35344001DOIregistry reference BACKGROUND:35344001
R0024549Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.
McCrimmon RJ, Diabetologia
2020Randomized trialPMID 31897524DOIregistry reference BACKGROUND:31897524